OTCMKTS:MEDIF MediPharm Labs (MEDIF) Stock Price, News & Analysis → Trump just won 2024 (From Porter & Company) (Ad) Free MEDIF Stock Alerts $0.06 -0.01 (-13.82%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$0.06▼$0.0750-Day Range$0.05▼$0.0752-Week Range$0.04▼$0.08Volume475,257 shsAverage Volume117,319 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get MediPharm Labs alerts: Email Address Ad Porter & CompanyTrump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. For the full story, click here. About MediPharm Labs Stock (OTCMKTS:MEDIF)MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products. In addition, the company offers cannabis related medical information and services; and medical cannabis clinic services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.Read More MEDIF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MEDIF Stock News HeadlinesApril 17, 2024 | finance.yahoo.comMediPharm Labs Corp. (MEDIF)March 29, 2024 | seekingalpha.comMediPharm Labs Corp. (MEDIF) Q4 2023 Earnings Call TranscriptMay 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. March 27, 2024 | investorplace.comMEDIF Stock Earnings: MediPharm Labs Reported Results for Q4 2023March 27, 2024 | prnewswire.comMediPharm Labs Provides Conference Call Recording DetailsMarch 27, 2024 | prnewswire.comMediPharm Labs Reports Fourth Quarter and Full Year ResultsMarch 25, 2024 | prnewswire.comMediPharm Labs Provides Update on German Cannabis LegalizationFebruary 7, 2024 | finanznachrichten.deMediPharm Labs Inc.: MediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health AuthorityMay 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. February 7, 2024 | finance.yahoo.comMediPharm Labs Achieves Pharmaceutical GMP Certification with Brazilian Health AuthorityNovember 14, 2023 | benzinga.comMediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial ReportNovember 14, 2023 | msn.comMediPharm Labs reports Q3 resultsOctober 25, 2023 | finance.yahoo.comMediPharm Labs Corp (MLZ.BE)October 25, 2023 | finance.yahoo.comMediPharm Labs Update on $9M Settlement Agreement - All Tilray Shares Sold and Converted to CashSeptember 20, 2023 | benzinga.comMediPharm Labs Breaks Free From Royalty Agreement, What It Means & What's NextAugust 31, 2023 | finance.yahoo.comMediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia PatientsAugust 14, 2023 | benzinga.comCannabinoid-Focused Pharma Stock Slides On Q2 Earnings Report, Here Are The DetailsAugust 14, 2023 | finanznachrichten.deMediPharm Labs Corp.: MediPharm Labs Reports Second Quarter Results with Doubling of Revenue and Record Margin GrowthAugust 10, 2023 | finance.yahoo.comMediPharm Labs Sets Date to Report Second Quarter 2023 Financial ResultsAugust 1, 2023 | benzinga.comMediPharm Delivers Cannabis Clinical Trial Material To US Research Partner And Provides Update On FDA StatusAugust 1, 2023 | finance.yahoo.comMediPharm Labs Makes First Delivery of Cannabis Clinical Trial Material to US Research Partner and Provides Update on US FDA StatusJune 26, 2023 | msn.comTwo Pot Companies Continue To Focus On Cannabinoid-Based Self-Emulsifying Drug Delivery SystemsJune 22, 2023 | finance.yahoo.comMediPharm Labs Announces Change of AuditorJune 9, 2023 | fool.comMediPharm Labs (OTC: MEDIF)May 10, 2023 | finance.yahoo.comMediPharm Labs Sets Date to Report First Quarter 2023 Financial ResultsMay 6, 2023 | theglobeandmail.comClosing Bell: Medipharm Labs Corp flat on Friday (LABS)April 25, 2023 | theglobeandmail.comClosing Bell: Medipharm Labs Corp flat on Tuesday (LABS)See More Headlines Receive MEDIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediPharm Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:MEDIF CUSIPN/A CIKN/A Webwww.medipharmlabs.com Phone(705) 719-7425FaxN/AEmployees166Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. David A. PidduckCEO & DirectorMr. Keith StrachanCo-Founder & PresidentMr. Greg HunterChief Financial OfficerMr. Patrick McCutcheonFounderMr. Saravan SubramaniamVice President of Operations & Supply ChainMr. Geoffrey MarrExecutive VP & General CounselMr. Brett MoonVice President of SalesMr. Kirk BinnsExecutive Vice President of Global AccountsMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors MEDIF Stock Analysis - Frequently Asked Questions How have MEDIF shares performed in 2024? MediPharm Labs' stock was trading at $0.0486 on January 1st, 2024. Since then, MEDIF stock has increased by 40.9% and is now trading at $0.0685. View the best growth stocks for 2024 here. How do I buy shares of MediPharm Labs? Shares of MEDIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:MEDIF) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediPharm Labs Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
